
RD-R167 378	CHARACTE TRYPANOS MEDICINE	RIZATION OF DMES BY MAC BRONX NY 1-C-1196	ANTIBO ROPHAGE	DY-DE	PENDEN ALBERT EICH E	T KILL EINST T AL.	ING OF EIN CO JAN 85	LL OF	1/	1
UNCLASSIFIED	DAMD17-8	1-C-1196					F/G 6	/5	ML	
	5 0									



MICROCOP

CHART

AD-A167 378

Î

<u>( کار انجا</u>

AD

Characterization of Antibody-Dependent Killing of Trypanosomes by Macrophages.

Final Report

David L. Rosenstreich, M.D. and Hellen C. Greenblatt, Ph.D.

January 1985

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND

Fort Detrick, Frederick, Maryland 21701

Contract No. DAMD17-81-C-1196

Albert Einstein College of Medicine Bronx, New York 10461

Approved for public release; distribution unlimited.

The findings in this report are not be construed as an official Department of the Army position unless so designated by other authorized documents.

0 9 1986




5 9 02 9

			REPORT DOCU	MENTATION	PAGE		
a. REPORT S	ECURITY CLASS	FICATION		16. RESTRICTIVE	MARKINGS		<u> </u>
	CLASSIFICATION	N AUTHORITY		3. DISTRIBUTION	AVAILABILITY O	F REPORT	
DECI ACCI		INGRADING SCHEDU	11 F		for public		
			/ <b>15</b> 19		ion unlimit		<u> </u>
PERFORMI	G ORGANIZAT	ION REPORT NUMBE	(R(S)	5. MONITORING	ORGANIZATION R	EPORT NUMBER	R(S)
a. NAME OF	PERFORMING		6b. OFFICE SYMBOL	7a. NAME OF MO	ONITORING ORGA	NIZATION	
Medicin	1e	College of	(if applicable)				
c. ADDRESS	(City, State, and	1 ZIP Code)		7b. ADDRESS (Cit)	y, State, and ZIP	Code)	
Bronx,	New York	10461					
	FUNDING / SPO	NSORING Army Medical	8b. OFFICE SYMBOL (If applicable)	9. PROCUREMENT		ENTIFICATION N	UMBER
		opment Comman		DAMD17-81-	C-1196		
c. ADDRESS	(City, State, and	ZIP Code)		10. SOURCE OF F			
Fort De	etrick			PROGRAM ELEMENT NO.	PROJECT NO. 3M1-	TASK NO.	WORK UNIT ACCESSION NO.
Frederi	ick, Maryl	and 21701-501	2	62770A	62770A871	AE _	074
2. PERSONA David I 3a. TYPE OF	REPORT	reich, M.D.; 13b. TIME C	-Dependent Killi Hellen C. Green OVERED	blatt, Ph.D. 14. DATE OF REPO	RT (Year, Month,	Day) 15. PAGE	
2 PERSONA David I 3a. TYPE OF Final F	REPORT	reich, M.D.; 13b. TIME C FROM <u>81/</u>	Hellen C. Green	blatt, Ph.D. 14. DATE OF REPO	RT (Year, Month,	Day) 15. PAGE	
2. PERSONA David I 3a. TYPE OF Final F 6. SUPPLEM	L AUTHOR(S) C. ROSENST REPORT REPORT ENTARY NOTAT COSATI	reich, M.D.; 13b. TIME C FROM 81/ FION CODES	Hellen C. Green OVERED	blatt, Ph.D. 14. DATE OF REPO 4 1985 Ja	RT ( <b>Year, Month,</b> . nuary	Day) 15. PAGE	e count 38
2. PERSONA David I 3a. TYPE OF Final F 6. SUPPLEMI 7. FIELD	L AUTHOR(S) C. ROSENST REPORT REPORT ENTARY NOTAT COSATI GROUP	reich, M.D.; 13b. TIME C FROM81/ FION	Hellen C. Green OVERED (9/15_TO_83/11/1 18. SUBJECT TERMS ( African T	blatt, Ph.D. 14. DATE OF REPO 4 1985 Ja Continue on reverse rypanosomes	RT (Year, Month, nuary a if necessary and	Day) 15. PAGE	E COUNT 38 Dock number) obulins
2. PERSONA David I 3a. TYPE OF Final F 6. SUPPLEMI 7. FIELD 06 06 9. ABSTRAC	L AUTHOR(S) L. ROSENST REPORT REPORT ENTARY NOTAT GROUP 13 03 T (Continue on	reich, M.D.; 13b. TIME CO FROM 81/ TION CODES SUB-GROUP reverse if necessary	Hellen C. Green OVERED (9/15_TO_83/11/1 18. SUBJECT TERMS ( African T Trypanoson Macrophage and identify by block (	blatt, Ph.D. 14. DATE OF REPO 4 1985 Ja Continue on reverse rypanosomes nes rhodesien es number)	RT (Year, Month, nuary a if necessary and nse	Day) 15. PAGE d identify by blo Immunoglo Complement	E COUNT 38 Dock number) obulins nt
2. PERSONA David I David I 3a. TYPE OF Final F 6. SUPPLEM 7 FIELD 06 06 9. ABSTRAC In like cel tion bet and medi function trypanos penetrat of compl by macro peritone trypanos	L AUTHOR(S) L. ROSENST REPORT REPORT ENTARY NOTAT COSATA GROUP 13 03 Continue on the presen 1 lines bi ween the a ate bindin in the ma omes in an e macropha ement is a phages. T al macrophone-bindin	reich, M.D.; 13b. TIME C FROM 81/ FROM 81/ FROM CODES SUB-GROUP reverse if necessary nce of specified and the specified of the specifi	Hellen C. Green OVERED 9/15 TO 83/11/1 18. SUBJECT TERMS ( African T: Trypanoson Macrophage and identify by block of ic antibody, mu: ma rhodesiense i ese products to somes to macropi ding assay and munofluorescence tead are phagoc co-factor in Ige rtial genetic re 7BL/6, BALB/c, However, 10 days	blatt, Ph.D. 14. DATE OF REPO 4 1985 Ja Continue on reverse rypanosomes mes rhodesien parasites <u>in</u> neutralize <u>in</u> hages <u>in vith</u> the ability of e assay. Try ytized by the G mediated bi egulation of and C3H/HeJ m s post-infect	RT (Year, Month, nuary if necessary and nse eal macropha vitro. The trypanosome ro and a hig of monoclona ypanosomes of e macrophage inding and a this phenom nice do not tion, cells	Dey) 15. PAGE didentify by block Immunoglo Complement ages and matere is a his infection gh coincide al antibody do not act: es. The Ci uptake of the menon. Not differ in from genet	e count 38 ock number) obulins nt acrophage- igh correla- in vivo ence between y to bind ively 3 component trypanosomes rmal their tically
2 PERSONA David I David I 3. TYPE OF Final F 6. SUPPLEM 7 FIELD 06 06 9 ABSTRAC 9 ABSTRAC 1 1 ike cel tion bet and medi function trypanos penetrat of compl by macro peritone trypanos suscepti resistan	COSATI REPORT REPORT COSATI ENTARY NOTATI GROUP 13 03 F (Continue on the presen 1 lines bi ween the a ate bindir in the ma omes in ar e macropha ement is a phages. T al macroph ome-bindir ble, BALB/ t, C57BL/6	reich, M.D.; 13b. TIME C FROM 81/ FROM 81/	Hellen C. Green OVERED (9/15 TO 83/11/1) (9/15 TO 83/11/1) (9/15 TO 83/11/1) (18. SUBJECT TERMS ( African T Trypanoson Macrophage and identify by block of ic antibody, mu: ma rhodesiense ese products to somes to macrop ding assay and munofluorescence tead are phagoc co-factor in Ig rtial genetic re 7BL/6, BALB/c, However, 10 day: more trypansom murine (P388D1	blatt, Ph.D. 14. DATE OF REPO 4 1985 Ja Continue on reverse rypanosomes mes rhodesien es number) rine peritone parasites <u>in</u> neutralize thages <u>in vith</u> the ability of e assay. Try ytized by the G mediated bi egulation of and C3H/HeJ to s post-infect es than did to and J774.2)	RT (Year, Month, nuary if necessary and nse eal macropha vitro. The trypanosome ro and a hig of monoclona ypanosomes of macrophage inding and this this phenom nice do not tion, cells those from a and human	Day) 15. PAGE didentify by block Immunoglo Complement ages and matere is a his infection gh coincide al antibody do not acts es. The Couptake of the nenon. Not differ in from genet infected ge (BB, CG, CS)	acrophage- igh correla- in vivo ence between y to bind ively 3 component trypanosomes rmal their tically enetically
2 PERSONA David I David I 3. TYPE OF Final F 6. SUPPLEM 7 FIELD 06 06 9. ABSTRAC 9. ABSTRAC 9. ABSTRAC 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	COSATI REPORT REPORT REPORT REPORT ENTARY NOTATION GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI GROUP 13 03 COSATI 10 COSATI 10 COSATI 10 COSATI 10 COSATI 10 COSATI 10 COSATI 13 03 COSATI 13 COSATI 14 COSATI 13 03 COSATI 14 C	reich, M.D.; 13b. TIME C FROM 81/ FROM 81/	Hellen C. Green OVERED 9/15 TO 83/11/1 18. SUBJECT TERMS ( African T Trypanoson Macrophag and identify by block ic antibody, mu ma rhodesiense ese products to somes to macrop ding assay and munofluorescence tead are phagoc co-factor in Ig rtial genetic re 7BL/6, BALB/c, However, 10 days more trypansom murine (P388D1	blatt, Ph.D. 14. DATE OF REPO 4 1985 Ja Continue on reverse rypanosomes mes rhodesien es number) rine peritone parasites <u>in</u> neutralize thages <u>in vith</u> the ability of e assay. Try ytized by the G mediated bi egulation of and C3H/HeJ these s than did the and J774.2) 21. ABSTRACT SE Unclassi	RT (Year, Month, nuary if necessary and nse eal macropha vitro. The trypanosome ro and a hig of monoclona ypanosomes of e macrophage inding and this phenomice do not this phenomic those from the and human CURITY CLASSIFIC	Day) 15. PAGE didentify by block Immunoglo Complement ages and matere is a his infection gh coincide al antibody do not acts es. The Couptake of the menon. Non differ in from genet infected ge (BB, CG, CS ATION	acrophage- igh correla- in vivo ence between y to bind ively 3 component trypanosomes rmal their tically enetically S, and DM)
2 PERSONA David I David I 3. TYPE OF Final F 6. SUPPLEM 7 FIELD 06 06 9. ABSTRAC 9. ABSTRAC 1 1 ike cel tion bet and medi function trypanos penetrat of compl by macro peritone trypanos suscepti resistan 20. DISTRIBU	COSATI REPORT REPORT ENTARY NOTATION GROUP 13 03 COSATI GROUP 13 03 CONTINUE ON the present 1 lines bi ween the at ate bindin in the material omes in an e macropha ement is a phages. The al macropha ome-bindin ble, BALB/ t, C57BL/CONTINUE ON	reich, M.D.; 13b. TIME C FROM 81/ FROM 81/	Hellen C. Green OVERED 9/15 TO 83/11/1 18. SUBJECT TERMS ( African T Trypanoson Macrophag and identify by block ic antibody, mu ma rhodesiense ese products to somes to macrop ding assay and munofluorescence tead are phagoc co-factor in Ig rtial genetic re 7BL/6, BALB/c, However, 10 days more trypansom murine (P388D1	blatt, Ph.D. 14. DATE OF REPO 4 1985 Ja Continue on reverse rypanosomes mes rhodesien es humber) rine peritone parasites <u>in</u> neutralize in hages <u>in vith</u> the ability of e assay. Try ytized by the G mediated bi egulation of and C3H/HeJ m s post-infect es than did to and J774.2) 21. ABSTRACT SE	RT (Year, Month, nuary if necessary and nse eal macropha vitro. The trypanosome ro and a hig of monoclona ypanosomes of e macrophage inding and this phenomice do not this phenomic those from and and human CURITY CLASSIFIC fied	Day) 15. PAGE didentify by block Immunoglo Complement ages and matere is a his infection gh coincide al antibody do not acts es. The Couptake of the menon. Non differ in from genet infected ge (BB, CG, CS ATION	E COUNT 38 Dock number) obulins nt acrophage- igh correla- in vivo ence between y to bind ively 3 component trypanosomes rmal their tically enetically S, and DM) SYMBOL

È

### SUMMARY

-In the presence of specific antibody, murine peritoneal macrophages and macrophage-like cell lines bind Trypanosoma rhodesiense parasites in vitro. Using a large bank of anti-WRATat 1.1 specific monoclonal antibodies, developed by Klaus Esser, Walter Reed Army Institute of Research, Washington, D.C., a high correlation was found between the ability of these products to neutralize trypanosome infection in vivo and mediate binding of trypanosomes to macrophages in vitro. There was also a high coincidence between function in the macrophage-binding assay and the ability of a monoclonal antibody to bind trypanosomes in an indirect immunofluorescence assay, (Hall and Esser, 1984). The mechanism by which trypanosomes penetrate macrophages was also investigated. The data suggest that these organisms do not actively penetrate macrophages, but instead are phagocytized by the macrophages. The mechanism underlying the enhancement of binding by fresh serum was analyzed, and the C3 component of complement was found to be important. Possible genetic control of macrophage function was also investigated. Normal peritoneal macrophages from C57BL/6, BALB/c, and C3H/HeJ mice do not differ in their trypanosomebinding ability. However, 10 days post-infection, cells from genetically susceptible, BALB/c mice bound more trypanosomes than did those from infected genetically resistant, infected C57BL/6 mice. A number of macrophage cell lines were analyzed for their trypanosome binding ability, Both murine (P388D1 and J774.2) and human (BB, CG, CS, and DM) macrophage cell lines were found to be capable of binding trypanosomes in the presence of specific Accesion For antisera.



### FOREWORD

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations. In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).

### TABLE OF CONTENTS

-

Ì

	Page
Title Page	
DD 1473	
Foreword	
Table of Contents	
Text of Final Report - Contract Goals and Progress	
A) Description of Macrophage binding assay.	2
B) Requirement for variant specific antibodies.	_2-3_
C) Analysis of the ability of monoclonal antibodies specific for	
discrete trypanosome antigenic determinants to mediate macrophage	
trypanosome binding <u>in vitro</u> .	3-8
D) Analysis of the activity of monoclonal antibodies <u>in vitro</u> .	<u> </u>
E) Determination of the immunoglobulin class dependence of	
macrophage-trypanosome binding <u>in vitro</u> .	_13
F) Analysis of the complement components and pathways required to	
enhance binding of <u>T. rhodesiense</u> to macrophages.	<u>13-19</u>
G) Characterization of macrophage functions and receptors involved	
in the <u>in vitro</u> system.	_19
H) Analysis of uptake by macrophages from resistant and	
susceptible mice.	20-23
I) Use of continuous cell lines as indicator cells.	23-25

•	
Discussion	<u>25–29</u>
References	<u>30–31</u>
• · · · ·	
Publications	
Personnel	

i.

Distribution List

### FINAL REPORT

For the period 15 September 1981 to 14 November 1983.

This contract was initiated September 1981 to characterize the phenomenon of macrophage binding of opsonized <u>T. rhodesiense</u> organisms <u>in vitro</u> (Greenblatt <u>et al</u> 1983).

The contract had the following goals:

كمكمكمك

 To determine the requirement for <u>T</u>. <u>rhodesiense</u> variant specific antibody in the assay,

2. To analyze the ability of hybridoma-derived <u>T</u>. <u>rhodesiense</u> special monoclonal antibodies to mediate trypansome binding in <u>vitro</u>,

3. To compare the ability of monoclonal antibodies which mediate binding of trypanosomes to macrophages <u>in vitro</u> with their ability to neutralize trypanosomes <u>in vivo</u>,

4. To determine the immunoglobulin class dependence of binding in vitro.

5. To analyze the effect of specific complement components in enhancing macrophage binding of trypanosomes,

6. To characterize macrophage functions and receptors active in this system,

7. To determine whether macrophages from mice which differ greatly in their natural resistance to infection with  $\underline{T}$ . <u>rhodesiense</u>, exhibit different capabilities in their binding and/or killing of trypanosomes <u>in vitro</u>, and

8. To test the trypanosome binding ability of murine and human macrophage cell line cells.

### A) DESCRIPTION OF MACROPHAGE BINDING ASSAY

In the presence of trypanosome-specific antibodies, cultured peritoneal macrophages or macrophage cell lines will bind and internalize <u>Trypanosoma</u> <u>rhodesiense</u> (Greenblatt, <u>et al</u>. 1983). The findings of Mac Askill <u>et.al</u>. (1980) also suggest that this <u>in vitro</u> system reflects a physiological pathway for trypanosome clearance.

In this assay, monolayers of resident peritoneal macrophages derived from C57BL/6 mice are cultured in tissue culture chamber slides (Lab Tek, Miles, Elkhart, IN) at  $37^{\circ}$ C in a 9% CO<sub>2</sub> atmosphere for 6-18h. At the end of the incubation period non-adherent cells are removed, fresh medium placed onto the remaining cells, and the slides incubated for a total period of 48-72h.

The monolayers are then exposed to trypanosomes in the presence of specific antibody (generated in rabbits or rats exposed to the appropriate trypanosome strain) or to WRATat 1-specific monoclonal antibodies developed by K. Esser (Walter Reed Army Institute of Research (WRAIR) Washington, D.C). After incubation of cultures with antibody and trypanosomes for 30 min. the cultures are washed, fixed with Giemsa stain, and then assayed by light microscopy. One hundred cells are counted and their binding and/or internalization of trypanosomes is recorded.

### B) REQUIREMENT FOR VARIANT SPECIFIC ANTIBODY

Injection of a clone of trypanosomes into mice will result in an antiserum that is specific for that clone (Campbell, <u>et al</u> 1979). Antibodymediated, complement dependent killing of trypanosomes <u>in vitro</u> requires variant-specific antibody (Diggs and Toussaint, personal communication) as do other antibody-dependent immune responses directed against trypanosomes. Some investigators have demonstrated that only variant-specific antibody will mediate the binding of <u>T. gambiense</u> to macrophages (Takayanagi and Nakatake,

1977). However, Cook (1981) found that antigen-specificity of rabbit immune sera was not a factor in the binding of <u>T. brucei</u> Etat 4 or <u>T. brucei</u> 427 to rabbit peritoneal cells. It was therefore necessary to test the need for specificity of antibody in mediating the attachment and internalization of trypanosomes to macrophages.

The results of a series of experiments to determine whether trypanosome binding to murine macrophages required variant-specific antibody are summarized in Table I. Normal mouse serum was unable to mediate binding of trypanosomes, regardless of which trypanosome variant was used. Rabbit anti-WRATat-300 (Wellcome) and the monoclonal antibody directed against WRATat-1 could only mediate binding of their respective trypanosomes.

There is also evidence for cross-reactivity between antibodies. WRATat-14 and WRATat-15 are two variant antigen types obtained after vector transmission of WRATat-1.1 (Esser <u>et al</u> 1982). Sera from three monkeys injected with these new variants were able to mediate binding of WRATat-1 trypanosomes to mouse resident peritoneal macrophages. The most likely explanation of this result is that WRAT at-14 and 15 share surface antigens in common with WRAT at-1.1.

Overall, the results of this series of experiments are consistent with the hypothesis, that antibody directed against a specific variant type was required to mediate binding of these parasites to macrophages.

C) <u>ANALYSIS OF THE ABILITY OF MONOCLONAL ANTIBODIES SPECIFIC FOR DISCRETE</u> TRYPANOSOME ANTIGENIC DETERMINANTS TO MEDIATE MACROPHAGE TRYPANOSOME BINDING IN VITRO

Klaus Esser of WRAIR, Washington, D.C., has fused immunoglobulinsecreting P3/X63-Ag8 or X63-Ag8.653 (Kearney, <u>et al</u>. 1979) myeloma cells lines and spleen cells from WRATat-1.1 infected mice. These fusions resulted in a

### TABLE I

## Effect of monoclonal antibody, and sera obtained from infected mice and monkeys on the binding of variant trypanosomes

2

Trypanosome Variant

	WRATat-300		WRATat-186
Serum	(Wellcome)	WRATat-1	<u>(EATRO 1886)</u>
Normal mouse sera	-	-	-
Rabbit anti-WRATat-300	+	-	-
Monoclonal 2.1B7.1 (anti-WRATat-1)	-	+	-
Monkey pre-bleed		-	
Monkey anti-WRATat-14		+	
Monkey anti-WRATat-15		+	

large number of hybridomas capable of reacting with, and neutralizing specific variants of parasites.

A large number of these monoclonal antibodies were provided to this laboratory for screening in our <u>in vitro</u> macrophage binding assay. The primary goal was to correlate <u>in vitro</u> binding to <u>in vivo</u> neutralization results, and determine whether the <u>in vitro</u> assay could replace <u>in vivo</u> neutralization tests or indirect fluorescence tests.

Neutralization of parasites, as carried out by the laboratory of K. Esser, (Hall and Esser, 1984) consisted of incubating parasites with the variant specific monoclonal antibody for 10 min and then injecting the suspension interperitoneally into the host mouse. Parasitemia was monitored by tail bleeding. The absence of parasites during the expected first wave of infection and throughout a 30 d period was considered proof that the tested antibody was capable of neutralizing a parasitic infection with a specific variant.

The ability of a variety of monoclonal antibodies to mediate <u>in vitro</u> binding of trypanosomes in the presence of exogenously added rat complement was determined (Table II). These <u>in vitro</u> results with each monoclonal antibody were compared with the <u>in vivo</u> neutralization results supplied to us by K. Esser.

Of the monoclonal antibodies assayed, 21.9% (32) were IgM, 31.3% (32) of the IgG1 subclass, 21.9% (32) of the IgG2a subclass, and 18.8% (6) of the IgG3 subclass. IgG2b and IgA each represented 3.1% of the total (or 1 monoclonal antibody each).

71.4% (5/7) of the IgM monoclonal antibodies mediated macrophage binding of trypanosomes (i.e., more than 12% of the macrophages bound trypanosomes). 100% of the IgG1 monoclonal antibodies (10/10) and 71.4% (5/7) of the IgG2a

		Percent	_
Monoclonal Antibody	In vivo	Macrophage	Ig
And I body	Neutralization	Binding	<u>Class</u>
31.4D1.6	0	9***	IgM
32.1A5.2	+	36	IgM
32.2A1.1	+	. 89	IgM
32.2A4.1	+	87	IgM
32.2A6.1	0	0	IgM
32.3F1.1	+	68	IgM
32.4G10	+	53	I gM
2.187.1	+	35	I gG1
* 6.7H11	0	56	IgGl
6.8C1.2	+	92	I gG1
* 6.10A4.1	0	51	IgGl
* 6.10F11.1	0	40	IgGl
* 6.1184.1	0	58	IgGl
6.11D5	+	87	IgGl
6.12E4	+	67	IğGl
16.2A12.2	+	87	IgGl
*16.3F1.4	0	43	IgGl
2.1D8.1	0	6	IgG2a
12.3D3.4	+	79	IgG2a
12.4F3.1	+	69	IgG2a
16.1A5.3	+	92	IgG2a
16.1A8.1	+	62	IgG2a
32.1A3.1	0	3	IgG2a
32.185.1	+	73	IgG2a
4.1G9.1	0	3	IgG2b
12.2E7.2	+	80	I gG3
*15.2H5.1	0	41	I gG3
31.465.1	0	9	I gG3
32.3B1.5.1	0	10	I gG3
32.401.5.1	0	6	IgG3
32.3B12.1	+	86	I gG3
6.11A9	+	15	IgA

# Comparison of the ability of monoclonal antibodies to neutralize trypanosomes <u>in vivo</u> and mediate <u>in vitro</u> binding to macrophages.

TABLE II

Indicates discrepancy between <u>in vivo</u> and <u>in vitro</u> findings. Data supplied by K. Esser (WRAIR). Less than 11% binding indicates negative binding.

\*\*\*

antibodies mediated binding of trypanosomes to macrophages. Only 50% (3/6) of the IgG3 monoclonal antibodies were active in this assay. The one IgG2b antibody tested was inactive, and the one IgA antibody tested had only weak activity.

Within all immunoglobulin classes and subclasses there were monoclonal antibodies which mediated binding of trypanosomes to macrophages. Work by Hall and Esser (1984), confirms that humoral immunity to WRATatl trypanosomes is associated with all classes of antibody.

Table II also compares the ability of monoclonal antibody to successfully neutralize <u>in vivo</u>, and their ability to mediate binding of parasites to macrophages <u>in vitro</u>.

There was 81.3% (26/32) coincidence between the results of neutralization by a monoclonal antibody and its capacity to bind parasites to macrophages. There were 6 monoclonal antibodies in which the <u>in vitro</u> binding assay was positive, but the <u>in vivo</u> neutralization test was negative. No antibodies neutralized <u>in vivo</u> but failed to mediate <u>in vitro</u> binding. 5 of the discrepant antibodies were of the  $IgG_1$ , subclass and one was an IgG3.

Hall and Esser (1984) described 3 morphological reactions when indirect fluorescence assays were performed with monoclonal antibody and WRATat-1 organisms. These were: 1) uniform, along the entire surface of the parasite, 2) focused about the region of the flagellar pocket and 3) no binding.

Four of the six antibodies that failed to neutralize <u>in vivo</u>, but mediated <u>in vitro</u> binding, bound to the region of the flagellar pocket (Table III). The remaining two antibodies did not produce detectable binding by the flourescent assay.

### TABLE III

### Monoclonal Antibodies (Mab) that can mediate <u>in vitro</u> binding to macrophages but are unable to neutralize infections <u>in vivo</u>.

Monoclonal Antibody	<u>Neutralization</u>	%_macrophage_binding	Pattern Binding in Flourescent Assay
6.10A4.1	0	51	Flagellar (pocket)
6.10F11.1	0	40	Flagellar (pocket)
6.11B4.1	0	58	Flagellar (pocket)
16.3F1.4	0	43	Flagellar (pocket)
6.7H11	0	56	none
15.2H5.1	0	41	none

\* Hall & Esser (1984).

Electron II

Section of the sectio

لادددند

#### D) ANALYSIS OF THE ACTIVITY OF MONOCLONAL ANTIBODIES IN VITRO

The ability of monoclonal antibodies to promote phagocytosis (in contrast to only external binding) of trypanosomes was also analyzed. There was a variation in the handling of trypanosomes after they were bound. For example, 31.4D1-6.1 was a non-functional monoclonal antibody of the IgM subclass (Tables I and II). It promoted neither attachment nor internalization of trypanosomes. Another monoclonal antibody of the IgM class, 32.2A1.1 mediated binding of parasites to 96% of the macrophages of which all had evidence of internalized trypanosomes. In contrast, monoclonal antibody 15.2H5.1 (IgG3) promoted binding by 63% of the macrophages, but fewer than 22% of these macrophages were able to phagocytose the parasites (Table IV).

Since some monoclonal antibodies were not able to mediate macrophage binding of trypanosomes <u>in vitro</u>, we analyzed whether addition of ineffective monoclonal products would interfere with the uptake that occurred in the presence of functional monoclonal antibodies. Also, since other laboratories (Hall & Esser, 1984; Ehrlich <u>et al</u>. 1982) have shown synergistic effects occurring when two monoclonal antibodies are mixed, we were interested in determining whether a similar phenomenon occurred in our system.

Resident peritoneal macrophages were incubated for 48 hours in Lab-Tek chambers. 20ul of the first monoclonal antibody and varying volumes (0-140ul) of the second monoclonal antibody were mixed in tubes. 0-140ul of normal mouse serum was added to keep total volumes constant. 150ul of these mixtures were added to an equal volume of WRATat-1 organisms at a concentration of 75 x  $10^6$  trypanosomes/ml. These slides were incubated for 30 min at  $37^{\circ}$ C, washed, stained, and the macrophages assayed for trypanosome-binding.

### TABLE IV

è

ŀ

# The relative ability of monoclonal antibodies to mediate binding and phagocytosis of trypanosomes

### % macrophages with trypanosomes that were:

Monoclonal Antibody	Bound only	Bound and/or internalized	Negative
IgM			
31.4D1.6.1 32.2A1.1 32.2A4.1 32.2A6.1 32.4G10	1 0 11 0 14	0 96 48 0 39	99 4 41 100 47
IgGl			
2.1B7.1 6.7H11 6.10A4.1 6.10F11.1 6.11B4.1 6.11D5.2 6.12E4	6 3 9 7 3 14 4	48 32 42 32 55 68 63	36 65 49 60 42 18 33
<u>I gG2a</u>			
16.1A5.3 16.1A8.1	36 9	49 53	15 38
IgG2b			
4.1G9.1	1	0	99
<u>1963</u>			
15.2H5.1 31.4G5.1 32.4G15.1	41 1 1	22 0 0	37 99 99
IqA			
6.11A9.0	5	10	85

Those monoclonal antibodies that had in previous assays exhibited a strong ability to promote binding, were not inhibited by the addition of monoclonal antibodies that had previously proven unable to mediate binding (Table V). In fact, the addition of increasing quantities of ineffective monoclonal antibodies frequently enhanced uptake compared to that which was obtained when the effective monoclonal antibodies were used alone. In the latter example, the antibodies by themselves were responsible for 79% and 34% binding respectively. When 140ul of 31.4G5.1 (a monoclonal antibody which was itself unable to mediate binding of parasites to macrophages) was added to the primary monoclonal antibody, uptake was increased to 93% and 64% (Table IV, lines 1 and 2).

Synergistic responses were also found with those monoclonal antibodies usually capable of only intermediate levels of binding. 20ul of 6.12E4 (d) in the absence of other monoclonal products promoted the binding of trypanosomes to 26% of macrophages (Table V, line 3). 6.7H11 (e) was a monoclonal product also able to mediate only low levels of binding (Table V, line 4). When these two monoclonal antibodies were combined, depending on the amount of secondary antibody added, 43%-54% of the macrophages were able to bind trypanosomes (Table V, lines 3 and 4).

Addition of as much as 7-fold the amount of nonfunctional antibodies to monoclonal products which were capable of promoting only low levels of binding did not inhibit the ability of the latter reagents to mediate binding of trypanosomes to macrophages (Table V, lines 5 and 6).

масторпа	of Monoclonal Ant		y MIXCUI	<b>E</b> 3		
				oclonal dy Mixtu	ire	<u>5</u>
First (#1) Mab Alone	Second (#2) Mab Alone	20 u 32 u		20 140	ul ul	
79(a)**	О(Ь)	73	3		93	

64

54

43

20

15

30

43

51

13

26

## nosome Rinding Induced by Mixtures

TABLE V

a.	32.2A1.1	(IgM)	f.	4.1G9.1	(IgG2b)
b.	31.4G5.1	(IgG3)	g.	6.11A9.0	(IgA)
с.	6.11D5.2	(IgG1)			
d.	6.12E4	(IgG1)			
e.	6.7H11	(IgG1)			

.

1.

2.

3.

4.

5.

6.

34(c)

26(d)

26(e)

11(f)

14(g)

32-14ul of the second monoclonal antibody (Mab) was added to 20ul of the first Mab. 150ul of the mixture was added to monolayers of macrophages \* simultaneously with 150ul of WRATat-1 trypanosomes.

\*\* Results represent % macrophages binding trypanosomes.

0(b)

26(e)

26(d)

14(g)

11(f)

## E) <u>DETERMINATION OF THE IMMUNOGLOBULIN CLASS DEPENDENCE OF MACROPHAGE-</u> TRYPANOSOME BINDING IN VITRO

Dr. Jeenan Tseung of WRAIR, Washington, D.C. provided us with antibody subclasses of rabbit anti-WRATat-300 (Wellcome) strain of <u>T. rhodesiense</u>. Serum was collected from an infected rabbit over a 4 week period, and antibody subclasses prepared by sequential ammonium sulfate precipitation (35-40%), cold precipitation, ion exchange chromatography on DEAE-cellulose, and affinity chromatography on immobilized staphylococcal protein A.

These fractions were demonstrated to be isotype specific IgM, IgG2a, and IgG2b, and were demonstrated to have no contamination with IgA. The starting material (hyperimmune serum) produced 83% binding of trypanosomes by macrophages. The cold-precipitable portion of IgM was able to mediate binding of trypanosomes to 80% of the macrophages both in the presence or absence of complement(Table VI). None of the other fractions were able to promote any attachment. These data suggest that only the IgM fraction of rabbit anti-WRATat-300 was functional in this assay.

## F) ANALYSIS OF THE COMPLEMENT COMPONENTS AND PATHWAYS REQUIRED TO ENHANCE BINDING OF T. RHODESIENSE TO MACROPHAGES

The role of complement in resistance to African trypanosomiasis remains controversial (Ferrante and Jenkins, 1978; Takayangai <u>et al</u>, 1974). In previous studies (Greenblatt <u>et al</u>, 1983) we found that in the presence of limiting amounts of specific antisera, complement enhanced the uptake and degradation of trypanosomes by macrophages. This phenomenon was examined in greater detail.

Anti-Wellcome antisera was heat-inactivated at 53<sup>0</sup>C for 90 min and used at various concentrations depending on the titer of the lot of antiserum

### TABLE VI

# Effect of fractions isolated from rabbit anti-trypanosome serum to mediate binding of trypanosomes

	% Binding of Trypanosomes to Macrophage			
	Cold Precipitable	Non-cold Precipitable		
Hyperimmune rabbit serum (83% binding)				
IgM without complement with complement	85 76	0 0		
IgG2a with or without complement	0	0		
IgG2b with or without complement	0	0		

used. In the presence of heat-inactivated antiserum diluted 1:35, only 13% of the macrophages bound trypanosomes. Upon addition of 6% fresh rat, guinea pig, or dog complement these percentages increased to maximum uptakes of 95%, 91%, or 68% respectively (Table VII).

Serum from guinea pigs genetically deficient in C4 (C4D<sup>gp</sup>, a gift from Dr. Robert O. Webster, NYS Kidney Disease Institute, Albany, NY) has no detectable C4 function (May et al., 1971) and therefore completely precludes activation of the complement cascade by the classical pathway (May <u>et al</u>, 1972). This serum was used to determine the requirement for C4 and the classical pathway to enhance binding of trypanosomes to macrophages in the presence of limiting dilutions of antiserum. The addition of C4D<sup>gp</sup> antitrypanosome antibody resulted in lower levels of total binding as compared to binding that occurred in the presence of intact guinea pig sera (66% vs 91%). Interestingly, there was no decrease in the phagocytosis of bound trypanosomes. These findings indicate that the classical complement pathway is involved primarily in the enhancement of binding of trypanosomes to macrophages.

To determine the role of the C3 component, dog serum deficient in functional C3 (C3D dog, a gift from Dr.Jerry Winkelstein, Johns Hopkins University, Baltimore, MD) was tested. When the C3D dog serum was added to anti-trypanosome antiserum there was only a slight decrease in the total phagocytosis of trypanosomes by macrophages (59% vs. 68%). However, the absence of C3 resulted in a significant decrease in the uptake of bound trypanosomes (25% vs 51%). These findings indicate that activation of complement via the alternative pathway and the C3 component are involved in the enhancement of phagocytosis of bound trypanosomes.

### TABLE VII

## Effect of the addition of complement deficient or intact sera on the binding of trypanosomes to macrophages.\*

Fresh serum	Macrophages with attached trypanosomes	Macrophages with at tached & internalized trypanosomes	% Total binding	Ratio of internalized trypanosomes to total binding
None	ND	ND	13	
C <sup>rat</sup>	22	73	95	.77
<sub>C</sub> guinea pig	2	89	91	.98
C4D <sup>guinea</sup> pig	4	61	66	.92
Cqod	17	51	68	.75
C3Dqoð	34	25	59	.42

\* 20ul of medium or serum intact or deficient in complement components was added to 145ul of anti-Wellcome antiserum diluted 1:35. 150ul of these mixtures were added to an equal volume of Wellcome trypanosomes at a concentration of 75x10<sup>6</sup> parasites/ml and added to Lab-Tek chambers containing 72 hr cultured macrophages. Slides were incubated 30min at 37C, washed, and stained.

Since it was possible that the cold inhibited trypanosome penetration as well as macrophage phagocytic activity, an alternate method for inhibiting macrophage uptake was used. Iodoacetic acid (IAA) is known to inhibit phagocytosis of sheep red blood cells (SRBC) by macrophages (Walker and Demus, 1975). IAA  $(1.5 \times 10^{-3})$  was therefore added to macrophages in the presence of SRBC and antiserum to SRBC. After incubation for 30 min at  $37^{\circ}$ C, macrophage monolayers were washed well with RPM1 1640 to remove all traces of the inhibitor, and in the presence of antiserum, trypanosomes were added to the cultures. Cultures were incubated again for 30 min at  $37^{\circ}$ C, and slides prepared.

As can be seen in control samples (Table VIII, lines 1 and 2), IAA did not significantly effect binding of SRBC (31% vs 22% for IAA and mediumtreated macrophages respectively). It did however effect internalization of opsonized sheep red blood cells. In the presence of IAA, 23.5% of the macrophages had internalized SRBC as compared to 49% of non-treated cells. The inhibition of binding caused by IAA was actually more complete than illus trated by these data since there were much fewer internalized SRBC in the IAA heated cells than in the non-treated (data not shown).

The effect of IAA was much more pronounced with the trypanosomes. When trypanosomes and anti-trypanosome antisera were added to washed macrophages previously exposed to IAA there was a 30-fold decrease in the numbers of macrophages that had internalized trypanosomes.

• These data confirm that <u>T</u>. <u>rhodesiense</u> trypanosomes do not actively penetrate macrophages, but that they are only taken up by phagocytosis.

### TABLE VIII

# Effect of Iodoacetic acid (IAA) on uptake of opsonized sheep red blood cells and trypanosomes.

Treatment of Macrophages	Particle <sup>a</sup>	At tached	Internalized	No Binding
IAA	SRBC	31.0	23.5	45.5
None	SRBC	22.0	49.0	29.0
IAA	Trypanosomes	69.5	1.5	29.0
None	Trypanosomes	49.0	44.0	7.0
		•		

<sup>a</sup> All particles were opsonized with an appropriate antibody.

These results indicate that both the classical and alternative complement pathways are involved in the enhanced binding and uptake of trypanosomes to macrophages in the presence of small amounts of specific antibody.

## G) CHARACTERIZATION OF MACROPHAGE FUNCTIONS & RECEPTORS INVOLVED IN THE IN VITRO SYSTEM

Some trypanosomes, such as <u>T. cruzi</u> are able to actively penetrate host cells. However, the mechanism of cellular uptake of <u>T. rhodesiense</u> is not known. We therefore investigated whether this organism actively penetrated cells, or whether its uptake was solely by cellular phagocytosis.

Macrophages were incubated with parasites at varying temperatures in order to dissociate binding of trypanosomes from the internalization or phagocytosis of trypanosomes. The ingestion of, as compared to the attachment of large particles by macrophages is highly temperature dependent. Macrophages bind and phagocytose well at  $37^{\circ}$ C, but at  $4^{\circ}$ C little internalization occurs (Silverstein, 1977). 150½1 of rat anti-Wellcome trypanosome antibody at dilutions of 1:2, 1:4, or 1:8, was added to an equal volume of Wellcome trypanosomes at a concentration of 75 x  $10^6/ml$  parasites and incubated for 30 min at  $4^{\circ}$ C or  $37^{\circ}$ C. 80% of all macrophages were capable of binding trypanosomes when the macrophages were incubated at 4<sup>0</sup>C, but only 19% of the macrophages internalized parasites (data not shown). In comparison, when cells were incubated at 37°C, 39-75% of the macrophages, depending on titer of mediating antibody, were capable of both binding and digesting trypanosomes. These findings suggest that in this assay, African trypanosomes do not actively penetrate murine macrophages, but instead are phagocytosed by the macrophages.

### H) ANALYSIS OF UPTAKE BY MACROPHAGES FROM RESISTANT AND SUSCEPTIBLE MICE.

第二 キャン・

In published reports (Greenblatt, <u>et al.</u>, 1980, 1984) we have demonstrated major differences in resistance among various mouse strains to <u>Trypanosoma rhodesiense</u> (EATRO 1886). C57BL/6 mice are most resistant, while BALB/c and C3H/HeJ mice are most susceptible to this organism. Since the cellular basis of these differences are not known, it was of interest to determine if macrophages from these strains differed in their ability to phagocytose trypanosomes. Resident macrophages were removed from non-infected C57BL/6, BALB/c, and C3H/HeJ mice and cultured for 48-72 hours before use. 0.15 ml of Wellcome trypanosomes at a concentration of 75 x  $10^6$ /ml was added to an equal volume anti-Wellcome antibody diluted from 1:5-1:25. Trypanosomes were permitted to adhere for 30 min at  $37^{0}$ C before suspensions were washed off.

As can be seen in Table IX, as the titer of anti-Wellcome antibody decreased, the percentages of macrophages taking up trypanosomes also decreased. However, there were no significant differences in uptake between the three mouse strains.

BALB/c and B6 mice were next infected with the EATRO 1886 strain of  $\underline{T}$ . <u>rhodesiense</u> and sacrificed on 10d postinfection. Peritoneal macrophages were removed from these mice and from non-infected age-matched controls, plated for 72 hours and assayed as usual with Wellcome trypanosomes and anti-trypanosome antibody. As can be seen from Table X, there was progressively less uptake of trypanosomes by macrophages from normal BALB/c and B6 as antiserum was diluted from 1:20-1:35. BALB/c macrophages removed 10d post infection took up trypanosomes more actively than normal controls at the higher dilutions of antiserum. The uptake of trypanosomes by infected B6 macrophages was also greater than the controls, but only at the highest titer of antiserum (1:20).

### TABLE IX

The binding of trypanosomes in the presence of various dilutions of antiserum by macrophages from three different mouse strains.

Dilution of anti-trypanosome antiserum	C57BL/6	BALB/c	C3H/HeJ
1:5	82∓7	75,5718	ND
1:10	95.5 <u>+</u> 2	87.5 <u>+</u> 7	ND
1:20	86.5 <u>+</u> 5	80.3 <u>+</u> 6	84.5 <u>+</u> 14
1:25	72.6 <u>+</u> 13	79,2 <u>+</u> 11	78.0 <u>+</u> 18

A mixture of 150ul of diluted anti-Wellcome antiserum was added to an equal volume of Wellcome trypanosomes to obtain final concentrations of antiserum of 1:5-1:25 and added to cultured macrophages obtained from 3 different strains of mice. After incubation at 37C for 30min, slides were treated as usual.

### TABLE X

The binding of trypanosomes in the presence of various dilutions of antiserum by macrophages from non-infected and infected mice.

### Dilution of Anti-Trypanosome Antiserum

PEC origin	<u>1:20</u>	<u>1:25</u>	<u>1:30</u>	<u>1:35</u>
Normal BALB/c	73.5 <u>+</u> 8	60 <u>+</u> 2	17.5±.5	6.5 <u>+</u> 3
d10 Infected BALB/C	86.5 <u>+</u> .5	44.5 <u>+</u> 8	37.5 <u>+</u> 4*	38.5 <u>+</u> 11 <sup>*</sup>
Normal B6	78.5 <u>+</u> 6	67 <u>+</u> 7	14.5 <u>+</u> 5	28 <u>+</u> 2
d10 Infected B6	30.5 <u>+</u> 4*	48 <u>+</u> 2	19 <u>+</u> 4	18 <u>+</u> 2*

Statistically significant (Student's T test)

ſ

A mixture of 150ul of diluted anti-Wellcome antiserum was added to an equal volume of Wellcome trypanosomes to obtain final concentrations of antiserum of 1:20-1:35 and added to cultured macrophages obtained from non-infected and

1:20-1:35 and added to cultured macrophages obtained from non-infected and infected BALB/c or C57BL/6 (B6) mice.

These findings indicate that trypanosome infection results in an increase in the phagocytic activity of macrophages. However observed macrophage strain differences do not seem to be of sufficient magnitude to account for the differences in survival. 

### I) USE OF CONTINUOUS CELL LINES AS INDICATOR CELLS

### 1. Murine Lines

Since cell collection for the in vitro assay is time consuming, and since the use of cells from living animals is a potential source of uncontrolled variability, it was important to determine if cell lines could be used as indicator cells in this assay. Five murine macrophage cell lines were therefore tested for their ability to bind and phagocytose trypanosomes in vitro. One line, J774.2, bound organisms very well (90%), but phagocytosed poorly (1%) (Table XI). J774.16, a functional variant of J774.2, also bound organisms well (92%+), and was slightly more phagocytic. J774.3.4 a Fcreceptor deficient mutant, bound organisms less well (51%+) than the parent cell. CTRM1, an adenyl cyclase deficient mutant, bound cells relatively poorly (33%), but surprisingly appeared to be the most phagocytic cell line. P388D1, another murine macrophage cell line, did not function as well in this assay as did the J774 set of cells, with only 33% of cells binding, and 17% phagocytosing organisms. Thus no murine macrophage cell line was found that functioned as well as normal macrophages. However, screening of additional lines may uncover one with greater functional activity. Furthermore, the presence of functional deficiencies between cell lines with defined biochemical abnormalities, may help to elucidite the relevant mechanisms by which macrophages bind trypanosomes.

### TABLE XI

# The ability of murine macrophage cell lines to bind trypanosomes in the presence of trypanosome specific antibody

		% Binding			
<u>Cell Line</u>	Origin	At tached At tached Properties	and Only	No Internalized	Binding
J774.2	murine reticulum cell sarcoma (J774) particles -secretes pla activator -possesses Fc- for IgG2a, Ig and IgG3	receptors	89	1	10
J774.16	variant of J774 oxidize gluco via the hexos monophosphate -produces H <sub>2</sub> 0 <sub>2</sub>	e shunt	80	12	8
J774.3.4	variant of J774.2 -decreased pha of IgG2a & Ig opsonized par -augmented IgG particle upta in presence o	G2b ticles 2a ke	51	0	49
CTRM1	variant of J774.2 deficient	-adenyl cyclase	10	23	67
P388D1	variant of murine macrophage-like cell from P388 leukemia cells -produces interleukin-l	-can bind antigen antibody complexes of mouse IgG2a and rabbit IgG	33	1	66

### 2. Human cell lines

We also screened a number of newly developed human cell lines for their ability to bind trypanosomes in the presence of anti-trypanosome antiserum.

Four human macrophage cell lines (BB, CG, CS and DM) were derived by Dr. Betty Diamond of Albert Einstein College of Medicine. All 4 cell lines produce lysozyme and collegenase, and are esterase positive. None of the cell lines are capable of producing Interleukin-1 (IL-1). Approximately 80% of the cells in each clone have complement receptors and all have Fc receptors as measured by uptake of opsonized erythrocytes.

In our hands, adherence of these cells to Lab-Tek chambers was poor. However, of those cells that did adhere, 49%-72% were able to bind Wellcome trypanosomes in the presence of specific antibody (Table XII ).

### DISCUSSION

The findings presented in this report demonstrate that the <u>in vitro</u> macrophage assay is a useful model system for analyzing the interaction between macrophages, trypanosomes and antibodies. One major advantage of this assay is for the screening of antibodies for their potential ability to neutralize trypanosomes <u>in vivo</u>. Of the 32 monoclonal antibodies tested, no antibody that was negative <u>in vitro</u>, had <u>in vivo</u> activity. However, the assay does generate some false positives and is therefore only useful as a first order screening method. Thus, six monoclonal antibodies that mediated binding to macrophages <u>in vitro</u>, were unable to neutralize <u>in vivo</u>.

Four of these bound exclusively to the flagellar pocket of the trypanosome, and this binding to the flagellar pocket could explain the discrepancy between the <u>in vivo</u> and <u>in vitro</u> results. The pocket of the parasite has traditionally been considered as a region through which much movement occurs. Also, antisera directed against <u>T. rhodesiense</u> caps

### TABLE XII

### The ability of human cell lines to bind trypanosomes in the presence of 1:20 anti-Wellcome antiserum

1000 To 1000 To 2000 To

Ż

<u>Cell Line</u>	Percent Binding Trypanosomes
BB	49
CS	52
DM	72

150 ul of 1:10 titer of anti-Wellcome antiserum was added to an equal volume of Wellcome trypanosomes and added to monolayers of the human cell lines.

to an area about the flagellar pocket and is sometimes internalized (Gardiner et al, 1983). It is therefore possible that antibodies bound to the flagellar pocket might be rapidly internalized. By the time the parasite had been introduced into the host the antibody would no longer exist on the surface and the organism would no longer be opsonized. This lack of opsonization would prevent removal of the parasite.

The discrepancy with monoclonal antibodies 6.7H11 and 15.2H5.1 which exhibit neither fluorescence or neutralization, but were able to promote binding of trypansomes to macrophages is harder to explain. (Table III). These conflicting results may be due to differing lots of monoclonal antibodies utilized in the two separate assays. In order to reconcile this discrepancy, these experiments will have to be repeated using aliquots of the same lot of monoclonal antibodies.

The assay is also useful for characterizing the type of interaction between macrophages and trypanosomes that is mediated by individual antibodies. Thus, while binding promoted by most antibodies is associated with parasite internalization, some antibodies seem to preferentially mediate binding only (Table IV). It is noteworthy that one of the antibodies that has this property (15.2H5.1), binds to the flagellar pocket, and does not neutralize trypanosomes <u>in vivo</u>.

Using this assay, it was also possible to demonstrate that some antibodies that were themselves unable to mediate binding, could enhance the activity of other antibodies (Table V). It is interesting how a monoclonal antibody, which by itself is unable to mediate binding or uptake of parasites by macrophages, is nevertheless able to enhance the binding potential of a second monoclonal antibody. Hall and Esser (1984) have also found in their system that a monoclonal antibody which was not able to bind to live

organisms, was nonetheless able to increase the binding of another monoclonal. However, in contrast to our findings, they were also able to demonstrate that some monoclonal antibodies were able to block others.

When the activities of natural antibodies (as opposed to monoclonal antibodies) were examined <u>in vitro</u>, it was found that only the IgM antibodies could mediate trypanosome binding by macrophages (Table VI). Other reports have indicated that antibodies of both IgM and IgG specific to trypanosomes appear within 3 weeks of infection (Seed <u>et al</u> 1969, Musoke <u>et al</u> 1981, Cook 1981). However, Musoke <u>et al</u> (1981) determined that along with IgM, the IgGI isotype, not the IgG2, was responsible for clearance of parasites in cattle which is consistent with our <u>in vitro</u> findings. We did not have any IgG1 fractions to assay so the question of IgG1 specificity for the parasite cannot be resolved.

These data differ from our findings with the monoclonal antibodies. In those experiments, it was found that monoclonal antibodies of all isotypes were capable of mediating binding to macrophages. Such diversity may reflect the nature of the monoclonal antibody generating system rather than a situation found "in nature". Whether only specific Ig subclasses are functional against trypanosomes is an important question, and will require additional experimentation for its resolution.

The assay also allows the analysis of the importance of serum components other than antibody in the uptake of trypanosomes by macrophages. It was found that serum complement is an important cofactor in this system, and that complement activation by both the classical and alternative pathways was involved (Table VII). Classical pathway activation was most important in the enhancement of binding of trypanosomes while intact C3 was important for internalization of already bound trypanosomes. These findings may be

important in helping to elucidate the relative role of non-specific host defense mechanisms involved in combating trypanosome infections.

The importance of macrophage function in determining murine host resistance to <u>T</u>. <u>rhodesiense</u> infection was also determined using this assay system. C57B1/6 mice are resistant to this infection, while BALB/c mice are susceptible. No difference in the endogenous ability of macrophages of these two strains to bind trypanosomes was found (Table IX), suggesting that genetically determined differences in resistance are not expressed in the resting function of these cells. However, the response of macrophages from these two strains to infection was significantly different (Table X). Whether this reflects a primary difference in macrophage function, or is a secondary manifestation of the infection remains to be established.

A variety of murine and human macrophage cell lines were also screened for their ability to bind and internalize trypanosomes <u>in vitro</u>. No lines were found to behave identically to normal macrophages. Thus, while these lines may be useful in examining the role of specific macrophage properties in this assay, those tested so far cannot be substituted for normal cells.

### REFERENCES

- Campbell, G.H., K.M. Esser, B.T. Wellde and C.L. Diggs. 1979. Isolation and characterization of a new serodeme of <u>Trypanosoma</u> <u>rhodesiense</u>. Am. J. Trop. Med. Hyg. <u>28</u>:974-983.
- Cook, R.M. 1981. At tachment of <u>Trypanosoma</u> <u>brucei</u> for rabbit peritoneal exudate cells. Int. J. Parasitol. <u>11</u>:149-156.
- Ehrlich, P.H., Moyle, W.R., Moustafa, Z.A., and R.E. Canfield. 1982. Mixing two monoclonal antibodies yields enhanced affinity for antigen. J. Immunol. <u>128</u>:2709.
- Esser, K.M., M.J. Schoenbechler and J.B. Gingrich. 1982. <u>Trypanosoma</u> <u>rhodesiense</u> blood forms express all antigen specificities relevant to protection against metacyclic (insect form) challenge. J. Immunol. <u>129</u>:1715-1718.
- Ferrante, A., and C.R. Jenkin. 1978. Evidence implicating the mononuclear phagocytic system of the rat in immunity to infections with <u>Trypanosoma lewisi</u>. Aust. J. Exp. Biol. Med. Sci. <u>56</u>:201.
- May, J., T. Gaither, L. Ellman. 1971. Complement function in sera of C4-deficient guinea pigs. J. Exp. Med. <u>134</u>:176.
- Gardiner, P.R., Finerty, J.F., Dwyer, D.M., Ito, S., and V. M. Nantulya. 1983. Capping in African trypanosomes. <u>In</u>: J. Parasitology Supplement. 58th Ann. Meet. Am. Soc. Parasitol. San Antonio, Texas. (abs. #203).
- Greenblatt, H.C., Rosenstreich, D.L., and C. O. Diggs. 1980. Genetic control of natural resistance to <u>Trypanosoma rhodesiense</u> in mice. <u>In</u>: Perspectives in Immunology: Genetic Control of Natural Resistance to Infection and Malignancy. E. Skamene (ed), Academic Press, pp. 89-95.
- Greenblatt, H.C., C.L. Diggs, M. Aikawa. 1983. Antibody-dependent phagocytosis of <u>T. rhodesiense</u> by murine macrophages. Am. J. Trop. Med. Hyg. <u>32</u>:34.
- Greenblatt, H.C. and D. L. Rosenstreich. 1984. <u>Trypanosoma rhodesiense</u> infection in mice: sex dependence of resistance. Infect. Immun. <u>43</u>;397.
- Hall, T. and K. Esser. 1984. Topological mapping of protective and nonprotective epitopes on the variant-specific surface glycoprotein of the WRATat 1 clone of <u>Trypanosoma brucei rhodesiense</u>. J. Immunol. <u>132</u>:2059.
- Kearney, J., A. Radbruch, B. Liesegang and K. Rajewsky. 1979. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. <u>123</u>:1548.

 MacAskill, J.A., P.H. Holmes, D.D. Whitelaw, I. McConnell, F.W. Jennings and G.M. Urquhart. 1980. Immunological clearance of <sup>75</sup>Se-labeled <u>Trypanosoma brucei</u> in mice. II. Mechanisms in immune animals. Immunology <u>40</u>:629. 

- May, J.E., Green, I., Frank, M.M. 1972. The alternate complement pathway in cell damage: antibody-mediated cytolysis of erythrocytes and nucleated cells. J. Immunol. <u>109</u>:595.
- Musoke, A.J., V.M. Nantulya, A.F. Barbet, F. Kironde and T.C. McGuire. 1981. Bovine immune response to African trypanosomes: specific antibodies to variable surface glycoproteins of <u>Trypanosoma brucei</u>. Parasite Immunol. <u>3</u>:97-106.
- Seed, J.R., R.L. Cornille, E.L. Risby and A.A. Gam. 1969. The presence of agglutinating antibody in the IgM immunoglobulin fraction of rabbit antiserum during experimental African trypanosomiasis. <u>59</u>:283-292.
- Silverstein, S.C. 1977. Endocytic uptake of particles by mononuclear phagocytes and the penetration of obligate intracellular parasites. Am. J. Trop. Med. Hyg. <u>26</u>:161.
- Takayanagi, T. and Y. Nakatake. 1977. <u>Trypanosoma gambiense</u>: The binding activity of antiserum to macrophages. Exp. Parasitol. <u>42</u>:21-26.
- Takayangi, T., Y. Nakatake, and G.L. Enriquez. 1974. Attachment and ingestion of <u>Trypanosome gambiense</u> to the rat macrophage by specific antiserum. J. Parasitol. <u>60</u>:336.
- Walker, W.S. and A. Demus. 1975. Antibody-dependent cytolysis of chicken erythrocytes by an <u>in vitro</u>-established line of mouse peritoneal macrophages. J. Immunol. <u>114:</u>765-769.

WRAIR U

#### DISTRIBUTION LIST

12 copies Director Walter Reed Army Institute of Research Walter Reed Army Medical Center ATTN: SGRD-UWZ-C Washington, DC 20307-5100

- 4 copies Commander US Army Medical Research and Development Command ATTN: SGRD-RMS Fort Detrick, Frederick, Maryland 21701-5012
- 12 copies Defense Technical Information Center (DTIC) ATTN: DTIC-DDAC Cameron Station Alexandria, VA 22304-6145
- 1 copy Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799
- l copy Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234-6100

